Faculty

Joselle M. Cook, M.B.B.S.

Clinical Studies

MGUS/MM Awareness and Genetics Insights Campaign (MAGIC) Rochester, Minn.
This proposal will determine the prevalence of MGUS among people of East African descent to improve the role of ancestral genetic diversity in myeloma research, allow an opportunity for early intervention, and reduce the disparity in diagnosing and monitoring precursor conditions for an incurable cancer which disproportionately affects those of African descent.
Phase 1b Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Patients With Relapsed/Refractory Multiple Myeloma (R5458-ONC-2012) Rochester, Minn.
This phase 1b trial is an open-label study designed to assess the safety, tolerability, and preliminary antitumor activity of REGN5458 in combination with other cancer treatments for patients with relapsed/refractory multiple myeloma (RRMM).

A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.
The purpose of this study is to investigate the Safety and Efficacy of CLN-619 (anti-MICA/MICB Antibody) in Patients with Relapsed and Refractory Multiple Myeloma.